Peter Heutink
About Peter Heutink
Peter Heutink Chief Scientific Officer
Peter Heutink serves as the Chief Scientific Officer, bringing extensive expertise in genetics and neurodegenerative diseases to the role. He has an accomplished academic and professional background, significantly contributing to various research and industry collaborations aimed at translating genetic findings into clinical applications.
Education and Expertise of Peter Heutink
Peter Heutink studied Biology at the University of Amsterdam. He earned his Ph.D. in Human Genetics from Erasmus University Rotterdam. His expertise lies in genome biology, particularly as it relates to neurodegenerative diseases. He has a robust background in leading research teams and advancing genetic understanding in diseases such as Parkinson's, frontotemporal dementia, and various developmental disorders.
Peter Heutink's Academic and Professional Background
Peter Heutink was a group leader and site speaker at the German Center for Neurodegenerative Diseases (DZNE) in Tübingen. He also served as a full professor of Genome Biology for Neurodegenerative Diseases at the Eberhard Karls University Tübingen, Germany. Additionally, he held an honorary professorship in Functional Genomics of Ageing and Neurodegeneration at the University Medical Center Groningen (UMCG), the Netherlands.
Achievements in Genetic Research by Peter Heutink
Peter Heutink has led teams that identified mutations in genes associated with diseases such as Parkinson’s, frontotemporal dementia, chorea, ataxia, hemochromatosis, porencephaly, and various developmental disorders. He has contributed significantly to genome-wide association studies for conditions like major depression, Tourette Syndrome, obsessive-compulsive disorders, and frontotemporal dementia. He is also a member of the steering committee of the Global Parkinson's Genetics Program.
Publications and Collaborations of Peter Heutink
Peter Heutink is the author or co-author of more than 400 peer-reviewed publications. His extensive publication record highlights his prolific contribution to the field of genetics and neurodegenerative disease research. He has also been involved in numerous industry collaborations, aiming to translate genetic research findings into clinical applications, underscoring his commitment to bridging the gap between research and clinical practice.